IGC Pharma Secures U.S. Patent for Microdose Cannabinoid Treatment of Stuttering and Tourette's Syndrome
I'm PortAI, I can summarize articles.
IGC Pharma Inc. has been granted U.S. Patent No. 12,491,200 for its microdose-based cannabinoid treatment targeting stuttering and Tourette’s Syndrome. This patent covers methods using ultra-low doses of THC, alone or with CBD, to address neural circuits linked to vocal disruptions and involuntary symptoms. This patent enhances IGC Pharma's intellectual property portfolio and supports its strategy in cannabinoid-based neurological therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments